Body Protection Compound-157 — a synthetic 15-amino-acid pentadecapeptide derived from a gastric protective protein, with one of the most extensive preclinical research bodies in the recovery category. Reclassified to Categoría FDA 1 in April 2026, restoring research access after a 2+ year compounding restriction.
BPC-157 was reclassified back to Categoría FDA 1 in April 2026 — a meaningful regulatory reversal after more than two years during which the compound was banned from compounding pharmacies under a Categoría 2 designation.
What Category 1 means: Under FDA's bulk substances framework, Category 1 indicates a substance that is appropriate for use in compounding. The reversal signals that the agency found insufficient evidence to maintain the safety-risk designation that drove the 2024 ban.
Why it matters for research: The reclassification re-opens legitimate research access channels that were closed during the Categoría 2 period. Clinics, research institutions, and individual researchers who relied on compounded BPC-157 can engage with the compound again through compliant channels. For an already-well-studied peptide with 300+ preclinical papers, this is a catalyst for renewed human-focused research design.
BPC-157 is on the agenda for FDA's Pharmacy Compounding Advisory Committee (PCAC) Day 1 hearing on July 23, 2026. The committee will evaluate BPC-157, KPV, and TB-500 for inclusion on the 503A Bulk Drug Substances List — the list that formally governs what compounding pharmacies may use.
Important: The MAHA/RFK Jr. political environment has elevated attention to compounding access for peptides. The PCAC process is a formal, evidence-based proceeding independent of political context — a positive recommendation is not guaranteed, and even a positive outcome requires further rulemaking before taking legal effect.
This page covers BPC-157's research profile. Regulatory classifications apply to compounding pharmacy use — this compound remains Investigación Use Only (RUO) for laboratory research purposes on this platform.
BPC-157 stands for Body Protection Compound-157 — a 15-amino-acid peptide (pentadecapeptide) with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Investigacióners synthesized it from a fragment of a naturally occurring protein found in human gastric juice. The stomach's remarkable ability to protect itself from its own acid led to the discovery of a protein family (BPC) that plays a key role in mucosal protection — and BPC-157 is a stable, synthetic version of one key active fragment.
What makes BPC-157 stand out in the research world is the breadth of tissue systems it has been examined in. Most peptides researchers study have a focused action — they operate in one tissue type through one mechanism. BPC-157 has been published in peer-reviewed research covering tendon healing, ligament repair, bone repair, muscle damage, intestinal tissue, corneal tissue, neural tissue, and aspects of the dopaminergic and serotonergic systems. This multi-system reach is unusual and drives continued research interest.
The peptide's molecular weight is approximately 1,419 Da. It's notable for its stability compared to many peptides that degrade rapidly in biological environments — BPC-157 is relatively stable in gastric conditions, a property that shaped the research models used to study it and is part of what makes it a practical research tool.
BPC-157 has one of the most extensive preclinical research bodies of any peptide in the recovery category — over 300 published studies spanning more than two decades, primarily from Croatian research groups working with it since the early 1990s. Here's what drives sustained research interest:
BPC-157 operates through several overlapping pathways rather than a single clean mechanism. In tendon and connective tissue models, it upregulates growth hormone receptors on tendon fibroblasts — the cells responsible for building the collagen matrix that makes tendons strong. By sensitizing these cells to growth hormone signals, it may amplify the natural repair response without requiring exogenous growth hormone administration.
Nitric oxide system: BPC-157 modulates nitric oxide (NO) synthesis and signaling. NO plays a dual role in tissue repair — at low concentrations it promotes vasodilation and nutrient delivery; BPC-157 appears to help maintain the right balance rather than simply elevating or suppressing NO production. This nuanced interaction with the NO system is a focus of mechanistic research.
Angiogenesis pathways: Upregulation of VEGF (vascular endothelial growth factor) is one of the most consistently documented effects of BPC-157 in tissue models. VEGF is the primary molecular signal for new blood vessel formation. By amplifying VEGF expression at repair sites, BPC-157 promotes vascular ingrowth — a critical step that limits healing speed in avascular or poorly vascularized tissues like tendons and ligaments.
Growth factor modulation: Beyond GH receptor upregulation, BPC-157 interacts with EGF (epidermal growth factor) and integrin signaling pathways that govern how cells sense and respond to their extracellular matrix. It upregulates matrix metalloproteinases (enzymes that clear damaged ECM) while simultaneously promoting new matrix synthesis — coordinating the breakdown/rebuild cycle of tissue remodeling.
Gut-brain axis: In GI research models, BPC-157 promotes mucosal healing through COX pathway modulation, cytokine regulation, and direct effects on intestinal epithelial cell migration. Investigación has also documented interactions with the enteric nervous system and connections to central dopaminergic activity — suggesting a gut-brain axis component that extends its mechanisms beyond local GI effects.
Imagine tissue repair like a construction project that's understaffed and under-resourced. The construction crew (fibroblasts, stem cells) is there and ready, but they're missing supplies, good roads to the site, and clear instructions. BPC-157 acts as a logistics coordinator who simultaneously: calls in more trucks (VEGF-driven blood vessel growth), hands the foreman a loudspeaker (GH receptor upregulation), clears the debris so crews can move (matrix metalloproteinase activity), smooths out the permit red tape (anti-inflammatory cytokine modulation), and calls the municipal water supply (NO pathway balance) to keep everything running. Multiple bottlenecks addressed at once.
Investigación Renuncia de responsabilidad: Lo siguiente refleja investigación clínica y preclínica publicada y no es consejo médico. Consulta a un profesional de la salud licenciado antes de tomar decisiones de salud.
BPC-157 has been studied across a range of administration routes and dosing protocols in published preclinical research. While large-scale human clinical trials remain limited, smaller pilot and case studies have documented dosing approaches. The following summarizes parameters as administered by researchers in published literature.
Published protocols describe BPC-157 as a lyophilized powder reconstituted in bacteriostatic saline or sterile water. Investigación protocols have noted stability in aqueous solution at 4°C for short-term storage (days to weeks), with lyophilized form stable at −20°C for extended periods. BPC-157's relative gastric acid stability is documented in the pharmacological literature — a property Sikiric et al. exploited to study oral administration in GI models (Sikiric et al., 2016, Curr Med Chem).
Published preclinical studies administered BPC-157 once or twice daily in the majority of protocols. Once-daily SC injection was the standard in Sikiric's long-running tendon and ligament series. Some systemic models used twice-daily dosing for the first week, transitioning to once-daily. No published data establishes a clear superiority of timing relative to meals or activity in human research contexts.
Referencias Clave: Sikiric P. et al. (1994). BPC-157 effects on healing of transected quadriceps tendon in rat. J Physiol Paris. · Sikiric P. et al. (2013). Stable gastric pentadecapeptide BPC-157. Curr Pharm Des. · Chang CH. et al. (2011). BPC-157 treatment increases tendon healing. J Appl Physiol. · Sikiric P. et al. (2018). Novel insight into gut-brain axis. Curr Neuropharmacology.
Achilles tendon repair models, rotator cuff injury, knee ligament healing. Among the best-studied applications with consistent findings across multiple animal models.
Inflammatory bowel disease models, gastric ulcer healing, intestinal anastomosis repair. Connected to its origin as a gastric-derived compound.
Traumatic brain injury models, dopaminergic pathway studies, spinal cord injury research. Growing interest in CNS applications following early positive results.
Angiogenesis models, wound healing vascularization, tissue perfusion studies. VEGF upregulation makes it a useful tool for studying blood vessel formation dynamics.
Crush injury and transection models, satellite cell activity, regeneration after ischemic injury. Studied alongside TB-500 in synergistic recovery models.
Corneal tissue healing, anterior segment repair. Emerging research area demonstrating the breadth of tissue types where BPC-157 mechanisms may be relevant.
BPC-157 was first isolated from gastric juice — scientists studying the stomach's protective chemistry stumbled onto something with repair potential far beyond the gut. Its broader effects across multiple tissue systems were a genuinely unexpected discovery from GI research.
Over 300 published preclinical studies span more than two decades of research — most originating from Croatian research groups working with it since the early 1990s. That depth of study in a single research group creates remarkable experimental consistency across publications.
Unlike many peptides, BPC-157 is remarkably stable in gastric acid — it doesn't degrade quickly in the acidic environments most peptides cannot survive. This stability makes it a practical and resilient research tool compared to more fragile peptide analogs.
Every batch of BPC-157 with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.